Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers Article
Full Text via DOI: 10.1016/j.jtho.2019.08.059
Web of Science: 000492162200010
International Collaboration